Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2712977 | 0.84 | MAPK1 (0.49) | MAPK1ATMALDH1A1 | |
| SCHEMBL978405 | 0.82 | MAPK1 (0.41) | XDHMAPK1ATMALDH1A1KDM4E | |
| SCHEMBL8886246 | 0.82 | XDH (0.44) | ARPELP1XDHMAPK1ATM | |
| SCHEMBL978445 | 0.82 | MAPT (0.46) | MAPK1ATMALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL13326243 | 0.80 | MAPK1 (0.45) | XDHMAPK1ATMALDH1A1KDM4E | |
| SCHEMBL16319378 | 0.77 | HPGD (0.56) | PTGER1ALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL31285153 | 0.77 | KDM4E (0.41) | MAPK1ATMALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2804058 | 0.77 | EPHX2 (0.44) | SCN9AMAPK1ATMSCN5A | |
| SCHEMBL8875124 | 0.76 | XDH (0.47) | ARPELP1XDHMAPK1HIF1A | |
| SCHEMBL31322831 | 0.76 | MRGPRX4 (0.41) | MAPK1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150045378-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2816032-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045378-A1 | AROMATIC RING COMPOUND | GPR119, GPR27, GPR4 | AR 75/4885PELP1 2608/4885XDH 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.